ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 4 out of 5

The Company develops antibody-based anticancer therapeutics.


Player Avatar zzlangerhans (99.85) Submitted: 12/1/2013 2:21:01 AM : Outperform Start Price: $13.75 IMGN Score: -69.84

I ended my underperform on ImmunoGen a little prematurely in order to align my CAPS picks with the zzporte portfolio, so I missed my long-awaited catharsis of the sudden discontinuation of the NORTH trial for futility. Nevertheless, the failure did provide me a better entry for this green thumb that supports our real life position of 650 shares at a cost basis of 16. Kadcyla royalties remain mostly theoretical but European approval of Kadcyla, positive results of TH3RESA, and upcoming data from the MARIANNE trial of Kadcyla as first line treatment in HER-2 positive breast cancer should help Immunogen with the investors that like to bank on potnetial.

Featured Broker Partners